Veradermics Incorporated Common Stock (MANE)
Stock · NYSE · Health Care
$97.93as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$106.64
Industry
Biotechnology: Pharmaceutical Preparations
About MANE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDM…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 37
- Website
- www.veradermics.com/
Fundamentals
- 1-day range
- $97$102.41
- Market cap
- $4.26B
- P/E (trailing)
- —
- P/E (forward)
- -36.44
- EPS (trailing)
- $-3.19
- Dividend yield
- —
- Beta
- -0.14
- Avg. volume
- 719.5K
52-week range
$32$131.24
Next earnings: November 12, 2026 · EPS estimate $-0.59
Forecasts
6 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$182
+85.8%
Median
$167
+70.5%
Low
$135
+37.9%
Veradermics Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- MANEVeradermics Incorporated Common Stock$97.53▼ 4.20%Market cap $4.26BP/E —$32$131.24
- ACADACADIA Pharmaceuticals Inc. Common Stock$29.13▼ 2.02%Market cap $4.39BP/E 12.85$19.69$30.96
- INDVIndivior Pharmaceuticals Inc. Common Stock$34.87▼ 1.22%Market cap $4.66BP/E 12.77$22.22$42.81
- VKTXViking Therapeutics Inc. Common Stock$32.15▼ 5.05%Market cap $3.80BP/E —$22.96$43.15
- ELVNEnliven Therapeutics Inc. Common Stock$57.82▼ 4.43%Market cap $3.53BP/E —$14.79$62.32
- GPCRStructure Therapeutics Inc. American Depositary Shares$47.38▼ 3.74%Market cap $3.44BP/E —$18.26$94.9
- TLXTelix Pharmaceuticals Limited American Depositary Shares$11.28▼ 0.84%Market cap $3.39BP/E —$6.28$12.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MANE Veradermics Incorporated Common Stock | $4.26B | — | $97.53 | ▼ 4.20% | $32$131.24 |
| ACAD ACADIA Pharmaceuticals Inc. Common Stock | $4.39B | 12.85 | $29.13 | ▼ 2.02% | $19.69$30.96 |
| INDV Indivior Pharmaceuticals Inc. Common Stock | $4.66B | 12.77 | $34.87 | ▼ 1.22% | $22.22$42.81 |
| VKTX Viking Therapeutics Inc. Common Stock | $3.80B | — | $32.15 | ▼ 5.05% | $22.96$43.15 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.53B | — | $57.82 | ▼ 4.43% | $14.79$62.32 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.44B | — | $47.38 | ▼ 3.74% | $18.26$94.9 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.39B | — | $11.28 | ▼ 0.84% | $6.28$12.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)SeekingAlpha · 8/27/2026
- Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimatebenzinga · 8/11/2026
- Veradermics Q2 EPS $(0.58) Beats $(0.65) EstimateBenzinga · 8/11/2026
- Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressYahoo · 8/11/2026
- Veradermics (MANE) Positioned to Disrupt Hair Loss MarketYahoo · 8/4/2026
- Veradermics (MANE) Price Target Increased by 23.12% to 166.77Fintel · 8/4/2026
Insider Activity
Insider Actions →Acquired
300.0K
Disposed
0
- SUVRETTA CAPITAL MANAGEMENT, LLC · May 1, 2026 · Grant151.0K @ $100
- SUVRETTA CAPITAL MANAGEMENT, LLC · May 1, 2026 · Grant149.0K @ $100
Institutional Ownership
March 31, 2026
- Total shares held
- 24.84M
- Total value held
- $1.57B
- Institutional holders
- 77
Top holders this quarter
- Unknown4.17M
- Unknown2.40M
- Unknown1.83M
- Unknown1.79M
- Unknown1.69M
- Unknown1.51M
- Unknown1.10M
- Unknown1.05M
- Unknown731.1K
- Unknown699.6K
See the full, filterable feed with live charts on the MarketWall dashboard.